A Randomised, Double Blind, Placebo-Controlled, Parallel-Group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.

Trial Profile

A Randomised, Double Blind, Placebo-Controlled, Parallel-Group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Actual patient number (84) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top